You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NCI's Nutritional Science Research Group is seeking more information about ways to study genetic variants and bioactives in food for potentially fighting cancer.
Advion is opening a new services facility in Indianapolis, and Eli Lilly will transition its drug discovery bioanalytical capability to the firm.
The partners will develop molecular diagnostic assays to be run on Luminex's xMAP platform.
BD will use UCL's biobanks of more than 200,000 patient samples to develop and validate biomarker assays.
Under a deal announced today, Proteome Sciences will measure candidate biomarkers for Alzheimer's disease for Eisai.
Under its subcontract with SAIC-Frederick, GNS will use its REFS platform to assess NCI data on several oncology drugs.
Computable Genomix, which is in the midst of changing its business model, will use the investment to fund a pilot study validating a process to develop genetic biomarker tests.
Research will be directed at gene expression in specific tumors to help radiologists "review results in a different and more comprehensive way."
Roche will use the company's multiplexed quantitative assays of cancer signaling pathway proteins.
The three partners will seek to discover and identify genetic and metabolite biomarkers for the development of new therapeutics against obesity.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.